Creating a new therapy using long noncoding RNA to repair heart damage
Developing Long Noncoding RNA Therapy for Precision Cardiac Repair
This study is testing a new treatment using special particles to deliver a molecule that helps protect the heart from damage after a heart attack, and it’s for people who have heart issues related to scarring in the heart.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia Univ New York Morningside NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10929434 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapy that utilizes long noncoding RNA (lncRNA) to treat cardiac fibrosis, a condition that can arise after heart attacks and lead to heart failure. The approach involves using lipid nanoparticles to deliver lncRNA-TARID, which has been identified as a key molecule in suppressing harmful cell activation in the heart. By targeting the underlying mechanisms of fibrosis, this therapy aims to improve heart function and patient outcomes. Patients may be involved in clinical trials to test the safety and effectiveness of this new treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced heart attacks or suffer from chronic cardiac conditions leading to fibrosis.
Not a fit: Patients with non-cardiac related health issues or those who do not have any history of heart disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking therapy that significantly improves recovery and quality of life for patients with heart disease.
How similar studies have performed: While the use of long noncoding RNA therapies is a relatively novel approach, preliminary studies have shown promise in similar applications for treating fibrotic diseases.
Where this research is happening
New York, United States
- Columbia Univ New York Morningside — New York, United States (Active)
Researchers
- Principal investigator: Cheng, Ke — Columbia Univ New York Morningside
- Study coordinator: Cheng, Ke
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.